Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

Abstract

We observed a statistically significant improvement in PFS and a nonstatistically significant increase in OS when docetaxel was administered immediately after front-line GC, without increasing toxicity or decreasing QOL.

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

“…in particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage iiiB/iV and nSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcinomas, 4 undifferentiated carcinomas), were enrolled. They received cisplatin (30 mg/sqm, days 1-3), oral etoposide (50 mg, days [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] and bevacizumab (5 mg/kg, day 3) every 3 weeks (mPEBev regimen). Patients who achieved an objective response or stable disease received maintenance treatment with bevacizumab in combination with erlotinib until progression.…”

Triplet Platinum-based Combination Sequential Chemotherapy Improves Survival Outcome and Quality of Life of Advanced Non-small Cell Lung Cancer Patients

“…Actually, the debate about maintenance therapy for advanced NSCLC had been re-ignited in recent years (Hosoe et al, 2003;Grossi et al, 2004;Chiappori et al, 2005;Pallis et al, 2006). The results of several randomized phase III studies reported showing a significant advantage of maintenance treatment in advanced NSCLC (Ciuleanu et al, 2007;Fidias et al, 2009;Cappuzzo et al, 2010). We noticed that all the trials with positive results had adopted different agents from the prior regimens as maintenance treatment.…”

“…Recently, several randomized phase III studies have documented improvement in outcome with the use of maintenance therapy for patients with advanced stage NSCLC (Ciuleanu et al, 2007;Fidias et al, 2009;Cappuzzo et al, 2010). Despite the beneficial role reported recently for maintenance therapy, platinum-based combinations had been rarely used as the maintenance regimen given the cumulative toxicities.…”

Advances in the prevention and treatment of lung cancer

“…[69][70][71] In addition, two phase III trials indicated that patients treated with maintenance docetaxol or pemetrexed following four cycles of platinum-based chemotherapy had improved progression-free survival in comparison with those on best supportive care. 72,73 Maintenance pemetrexed also improved overall survival. 73 Despite these advances, fiveyear survival in stage IIIB-IV NSCLC remains very poor, and novel targeted agents are being sought.…”